MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70812

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.

Wisch Julie K, McKay Nicole S, Zammit Matthew, Christian Bradley T, Schultz Stephanie A, Millar Peter R, Ryan Natalie S, Cash David M, Belder Christopher R S, Chrem Patricio, Cruchaga Carlos, Ibanez Laura, Jucker Mathias, Yakushev Igor, Day Gregory S, Murphy Mei, Llibre-Guerra Jorge, Aguillon David, Roh Jee Hoon, Xiong Chengjie, Wang Guoqiao, Li Yan, Schindler Suzanne E, Jack Cliff, McDade Eric, Bateman Randall J, Benzinger Tammie L S, Ances Beau M, Dominantly Inherited Alzheimer Networ, Betthauser Tobey, Gordon Brian

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION

Preclinical Alzheimer's disease (AD) can be described relative to biomarker positivity onset time.

METHODS

We estimated time from amyloid positivity (A+) using sampled iterative local approximation (SILA) in a longitudinal autosomal dominant AD (ADAD) sample (N = 379) with amyloid positron emission tomography. We compared (1) predicted age at A+ to imputed age, (2) estimated age at A+ to estimated age at symptom onset, and (3) variance in cognitive performance explained.

RESULTS

Mean error between imputed and SILA-estimated age at A+ (N = 26) was 1.15 years. Age at A+ explained 39% of estimated years to symptom onset (EYO) variance. Time from A+ explained 19% of cognitive composite variance and 14% of Clinical Dementia Rating Sum of Boxes CDR-SB variance; EYO explained 43% and 57%, respectively.

DISCUSSION: SILA estimates A+ age in ADAD with reasonably good accuracy. SILA-estimated time from A+ describes the start of pathology, but the time from A+ onset to symptoms is variable in ADAD and better described by EYO.

HIGHLIGHTS: Amyloid chronicity predicts a 14-year preclinical AD phase in ADAD. SILA accurately estimates age at A+ (MAE < 2 years). EYO outperforms chronicity in predicting symptom onset. APP mutation carriers show atypical amyloid accumulation. Chronicity models help reveal AD heterogeneity in preclinical stages.

Для цитирования: Wisch Julie K, McKay Nicole S, Zammit Matthew, Christian Bradley T, Schultz Stephanie A, Millar Peter R, Ryan Natalie S, Cash David M, Belder Christopher R S, Chrem Patricio, Cruchaga Carlos, Ibanez Laura, Jucker Mathias, Yakushev Igor, Day Gregory S, Murphy Mei, Llibre-Guerra Jorge, Aguillon David, Roh Jee Hoon, Xiong Chengjie, Wang Guoqiao, Li Yan, Schindler Suzanne E, Jack Cliff, McDade Eric, Bateman Randall J, Benzinger Tammie L S, Ances Beau M, Dominantly Inherited Alzheimer Networ, Betthauser Tobey, Gordon Brian. Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70812.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.